Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;4(1):e00014.
doi: 10.1002/psp4.14. Epub 2015 Jan 28.

Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model

Affiliations

Evaluating the Use of Linear Mixed-Effect Models for Inference of the Concentration-QTc Slope Estimate as a Surrogate for a Biological QTc Model

Y Huh et al. CPT Pharmacometrics Syst Pharmacol. 2015 Jan.

Abstract

In concentration-QTc modeling, oscillatory functions have been used to characterize biological rhythms in QTc profiles. Fitting such functions is not always feasible because it requires sufficient electrocardiograph sampling. In this study, drug concentration and QTc data were simulated using a published biological QTc model (oscillatory functions). Then, linear mixed-effect models and the biological model were fitted and evaluated in terms of biases, precisions, and qualities of inferences. The simpler linear mixed-effect model with day and time as a factor variables provided similar accuracy of the concentration-QTc slope estimates to the complex biological model and was able to accurately predict the drug-induced QTc prolongation with less than 1 ms bias, despite its empirical nature to account for biological rhythm. The current study may guide a concentration-QTc modeling strategy that can be easily prespecified, does not suffer from poor convergence, and achieves little bias in drug-induced QTc estimates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box and whisker plots of the estimation errors for drug effect model parameters in different Tmax scenarios of TQT study design. Models 1, 2, and 3 represent linear mixed effects models 1, 2, and 3, respectively, and the biological model represents a reduced model consisting of only one cosine function. Boxes denote the 25th and 75th percentiles and the filled circles inside the box denotes the median. Whiskers represent the 5th and 95th percentiles.
Figure 2
Figure 2
Coverage probability of slope estimates and false positive slopes. (a) Coverage probability of slope estimates containing the true slope calculated with 90% confidence intervals of slope estimates in 5 ms QTc prolongation scenario and (b) % false positive slopes of linear mixed effects models in the no QTc prolongation scenario (95% confidence interval excludes 0). Dashed line represents the 2.5% type 1 error.
Figure 3
Figure 3
Box and whisker plots of the estimation errors for drug effect model parameters in different Tmax scenarios of phase 1 study design. Models 1, 2, and 3 represent linear mixed effects models 1, 2, and 3, respectively. Boxes denote the 25th and 75th percentiles and closed circle inside the box denotes the median. Whiskers represent the 5th and 95th percentiles.
Figure 4
Figure 4
Box and whisker plots of the estimation errors for ddQTc in different Tmax scenarios of both TQT and phase 1 studies. Linear mixed effect model 2 was selected as the best model and difference between true ddQTc (true concentration × true slope) and model-predicted ddQTc (observed concentration x slope estimates) were calculated in ms. Boxes denote the 25th and 75th percentiles and closed circle inside the box denotes the median. Whiskers represent the 5th and 95th percentiles.

References

    1. Fenichel RR, et al. Drug-induced torsades de pointes and implications for drug development. J. Cardiovasc. Electrophysiol. 2004;15:475–495. - PMC - PubMed
    1. International Conference on Harmonisation. Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed. Regist. 2005;70:61134–1135. - PubMed
    1. Florian JA, Tornoe CW, Brundage R, Parekh A. Garnett CE. Population pharmacokinetic and concentration—QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J. Clin. Pharmacol. 2011;51:1152–1162. - PubMed
    1. Boos DD, Hoffman D, Kringle R. Zhang J. New confidence bounds for QT studies. Stat. Med. 2007;26:3801–3817. - PubMed
    1. Hutmacher MM, Chapel S, Agin MA, Fleishaker JC. Lalonde RL. Performance characteristics for some typical QT study designs under the ICH E-14 guidance. J. Clin. Pharmacol. 2008;48:215–224. - PubMed

LinkOut - more resources